d special and acquisition-related charges
(f) Included in cumulative effect in change in accounting principle, net
SCHERING-PLOUGH CORPORATION
Report for the period ended December 31 (unaudited):
GAAP Net Sales by Key Product
(Dollars in millions) Fourth Quarter Full Year
2007 2006 % 2007 2006 %
GLOBAL
PHARMACEUTICALS a/ $2,963 $2,211 34% $10,173 $8,561 19%
REMICADE 455 337 35% 1,648 1,240 33%
NASONEX 271 253 7% 1,092 944 16%
PEGINTRON 239 208 15% 911 837 9%
TEMODAR 234 189 23% 861 703 22%
CLARINEX /
AERIUS 174 164 6% 799 722 11%
CLARITIN RX 93 78 19% 391 356 10%
AVELOX 115 103 12% 384 304 26%
INTEGRILIN 91 85 7% 332 329 1%
REBETOL 71 75 (6%) 277 311 (11%)
CAELYX 66 49 33% 257 206 25%
INTRON A 57 57 - 233 237 (2%)
SUBUTEX /
SUBOXONE 57 51 11% 220 203 8%
PROVENTIL /
ALBUTEROL CFC 41 55 (25%) 207 203 2%
ASMANEX 41 36 16% 162 103 57%
ELOCON 37 33 10% 156 141 11%
FORADIL 25 28 (11%) 102 94 8%
NOXAFIL 29 10 N/M 89 19 N/M
FOLLISTIM c/ 57 - N/M 57 - N/M
NUVARING c/ 45 - N/M 45 - N/M
<
'/>"/>SOURCE Schering-Plough Corporation Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 Related biology technology :1.
Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test2.
Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute3.
FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma4.
Schering-Plough Announces Sugammadex New Drug Application Filed in Japan5.
Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA6.
Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference7.
Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result8.
Schering-Plough Wins Three of Scrips Top Pharma Industry Awards9.
Schering-Plough Completes Acquisition of Organon BioSciences10.
Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.11.
Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference